We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Rusk - no need to.
I know where this share price is going - conservative & inaccurate broker notes, won't make any difference to the eventual outcome.
IMHO
Trader
You may want to share these points with Arden. Clowns.
Someone did likewise (differing context) on ODX!
Just a quick update & refresher, for any new researchers following RNS on 201020.
A few key reasons to invest in ORPH, as follows:
- A world leader in testing vaccines via Controlled Human Infection Models (CHIMs)
- Confirmed ~£40 million contract for Covid CHIM’s with UK Governments
- Near term ~£8 million plus per contract, for Covid CHIM’s with multiple vaccine co’s
- Planning in progress for global Covid CHIM’s licensing deals i.e.USA & Australia
- Expansion of lab facilities with UK Gov, to cope with anticipated on going demand
- New high revenue post Phase 3 Covid trial vaccine testing
- Near term large special dividend from sale of Imutex (or NASDAQ listing)
- Near term large special dividend from data deal with wearable or smart phone co’s
- Huge & recurring future anticipated revenues from both Covid & Non Covid services
- Excellent CEO Cathal Friel and his team, who deliver on what they say they will do
- CEO with ‘skin in the game’, investing £2.5 million of his own cash (large % holder)
- Low risk ‘picks and shovel’ company, with a ‘large moat’ in a niche & hot sector
- Large Genomic Health Data Platform with significantly very high revenue potential
- Regular anticipated annual normal dividends from surplus cash
- Multiple valuable assets i.e. 24 bed London clinic & lab, 8x challenge studies etc
- Cash generating & profitable (~£15 million cash), within a growing global market
- Commitment to no future placings from CEO, who is ‘locked’ in for next two years
- Probable future takeover bid from large pharma service’s company
- Low market cap, relative to likely future revenues, assets and high growth prospects
For further research, any new investors may wish to view some video presentations, from our CEO Cathal Friel, as per link below:
https://www.openorphan.com/news-and-media/video-library
Additionally, there are numerous posts from knowledgeable and experienced investors on this board, with associated links and rationale.
Hopefully this may assist.